LISATA THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. FORM 10-K SUMMARY
None.
Index
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in Basking Ridge (Bernards Township), State of New Jersey, on February 29, 2024.
LISATA THERAPEUTICS, INC.
By: /s/ David J. Mazzo, PhDName: David J. MazzoTitle: Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ David J. MazzoDavid J. Mazzo, PhD | Director and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer) | February 29, 2024 |
| /s/ Gregory B. BrownGregory B. Brown, MD | Chairman of the Board of Directors | February 29, 2024 |
| /s/ Mohammad AzabMohamad Azab, MD, MBA | Director | February 29, 2024 |
| /s/ Cynthia L. FlowersCynthia L. Flowers, MBA | Director | February 29, 2024 |
| /s/ Heidi HensonHeidi Henson | Director | February 29, 2024 |
| /s/ Steven M. KloskSteven M. Klosk, JD | Director | February 29, 2024 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.